"We have been wanting to get into injectables for the longest time but we wanted to get into differentiated products. We really liked the Nanomi technology," managing director Nilesh Gupta told Reuters.
"It's going to be a while before we get it translated into products but we were very interested in acquiring the technology and then build off it," he said.
Lupin's net profit in the December quarter rose 42% to Rs. 4.8 billion ($76.61 million) on the launch of new drugs in its key US market, including the generic version of Eli Lilly & Company's Cymbalta used for treating major depressive disorder.
Analysts had expected Lupin's December-quarter net profit to be at Rs. 4.3 billion, according to Thomson Reuters data.
The company expects to maintain its current pace of launch of four to five generic drugs each quarter in the United States, which accounted for 45% of its sales in the third quarter, in the near future, Gupta said.
Shares of Lupin, which has a market value of more than $6 billion, rose as much as 4.9% after the results.